Sunitinib

Sunitinib was approved on January 26, 2006 by FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib is a small-molecule which is administered orally and it is multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs and other RTKs including RET, CSF-1R, and flt3.

Brands
SUTENT SUTENT SUTENT
Adult Dose
Neonatal
Paedriatic
Characteristics
It belongs to Receptor tyrosine kinase (RTK) inhibitor pharmacological group on the basis of mechanism of action.
Contraindications
Sunitinib is contraindicated in conditions like Hypersensitivity to the drug.
Effects
The symptomatic adverse reactions produced by Sunitinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Diarrhea, Stomatitis, Dyspepsia, Taste disturbance, Skin discoloration, Hair discoloration, Swelling, GI disorders, Skin dryness, Cracking of skin, Mouth sores, Skin thicking, Blister or rash on the palms of the hands and soles of the feet, Mouth irritation.
Indications
Sunitinib is primarily indicated in conditions like Gastrointestinal stromal tumour, Renal carcinoma.
Interactions
Sunitinib is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAtazanavirMay increases sunitinib concentrations.CarbamazepineMay decrease sunitinib concentrations.ClarithromycinMay increases sunitinib concentrations.DexamethasoneMay decrease sunitinib concentrations.Indinavir (Sulphate)May increases sunitinib concentrations.Itraconazolemay increases sunitinib concentrations.Ketoconazolemay increases sunitinib concentrations.Nefazodone (HCl)May increases sunitinib concentrations.NelfinavirMay increases sunitinib concentrations.Phenobarbital SodiumMay decrease sunitinib concentrations.Phenytoin (Na)May decrease sunitinib concentrations.RifabutinRifampicinMay decrease sunitinib concentrations.RitonavirMay increases sunitinib concentrations.SaquinavirMay increases sunitinib concentrations.St.Johns Wort ExtractMay decrease sunitinib concentrations. St. Johns Wort may decrease its plasma concentrations unpredictably. Patients receiving sunitinib should not take St. Johns Wort concomitantly.TelithromycinMay increases sunitinib concentrations.VORICONAZOLEVoriconazole may increase the serum concentration of sunitinib by decreasing its metabolism.Consider alternate therapy or monitor for changes in the therapeutic and adverse effects These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to patients suffering from Kidney dysfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Patients should be advised to inform their health care providers of all concomitant medications, including over-the-counter medications and dietary supplements. Grapefruit may also increase plasma concentrations of sunitinib. sunitinib dose modification is recommended in patients using concomitant CYP3A4 inhibitors or inducers.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.